Caution: TOP1 ADC immediately after TOP1 ADC
Giving a second ADC with the same kind of payload straight after the first often does not work well.
Retrospective series (ESMO Breast 2026 SATEEN/BRE-354 and others) show shorter PFS for the second TOP1-payload ADC, particularly when given back-to-back. Some data suggest an intervening chemotherapy restores sensitivity. Prospective sequencing trials are ongoing.
Pages like this
not linked directly; found by shared links- TrialASCENT-03
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast02
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast01
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, HR-positive / HER2-negative breast cancer.
- PairingTROP2 PET → TROP2 ADC selection
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Datopotamab deruxtecan, Triple-negative breast cancer (TNBC).
- TrialASCENT
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Sacituzumab govitecan, Triple-negative breast cancer (TNBC).
- TrialTROPION-Breast05
Shares TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET, Datopotamab deruxtecan, Triple-negative breast cancer (TNBC).
- IdeaSequencing HER2 ADCs by payload after T-DXd
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, ADC sequencing, Trastuzumab deruxtecan.
- IdeaRegistry-embedded randomisation of treatment order in routine care
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, ADC sequencing, HR-positive / HER2-negative breast cancer.